Christopher Stroh
About
Christopher Stroh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Christopher Stroh has authored 78 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Christopher Stroh's work include Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (25 papers) and Cancer Genomics and Diagnostics (16 papers). Christopher Stroh is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (25 papers) and Cancer Genomics and Diagnostics (16 papers). Christopher Stroh collaborates with scholars based in Germany, United States and Spain. Christopher Stroh's co-authors include Klaus Schulze‐Osthoff, Eric Van Cutsem, Anatoly Makhson, Sabine Tejpar, Philippe Rougier, Claus-Henning Köhne, Johannes Nippgen, J. Załuski, Gunnar Folprecht and G. Bodoky and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
Christopher Stroh
75 papers receiving 7.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher Stroh Germany | 28 | 5.6k | 2.5k | 2.0k | 1.7k | 1.5k | 78 | 8.0k | ||
| Tae‐You Kim South Korea | 48 | 4.3k 0.8× | 2.5k 1.0× | 2.0k 1.0× | 1.3k 0.8× | 1.5k 1.0× | 189 | 7.6k | ||
| Mario Scartozzi Italy | 44 | 3.7k 0.7× | 2.1k 0.8× | 1.7k 0.8× | 1000 0.6× | 953 0.6× | 343 | 6.4k | ||
| Scott M. Wilhelm United States | 28 | 2.8k 0.5× | 1.6k 0.7× | 3.5k 1.7× | 1.6k 1.0× | 1.7k 1.1× | 70 | 9.0k | ||
| Hans Prenen Belgium | 41 | 4.0k 0.7× | 2.6k 1.0× | 2.6k 1.3× | 976 0.6× | 653 0.4× | 207 | 8.6k | ||
| Robert R. McWilliams United States | 46 | 5.9k 1.1× | 1.9k 0.8× | 2.4k 1.2× | 1.1k 0.7× | 742 0.5× | 206 | 8.4k | ||
| Weijing Sun United States | 41 | 4.5k 0.8× | 1.4k 0.6× | 2.2k 1.1× | 908 0.5× | 1.1k 0.7× | 199 | 7.9k | ||
| Li‐Tzong Chen Taiwan | 41 | 2.6k 0.5× | 1.8k 0.7× | 2.4k 1.2× | 1.0k 0.6× | 1.2k 0.8× | 296 | 7.3k | ||
| Moritz Koch Germany | 46 | 4.6k 0.8× | 1.5k 0.6× | 2.2k 1.1× | 667 0.4× | 943 0.6× | 98 | 7.8k | ||
| Teppei Morikawa Japan | 43 | 5.2k 0.9× | 2.3k 0.9× | 3.4k 1.7× | 2.1k 1.2× | 346 0.2× | 207 | 9.4k | ||
| Ferry A.L.M. Eskens Netherlands | 43 | 2.9k 0.5× | 1.5k 0.6× | 2.6k 1.3× | 601 0.4× | 694 0.5× | 161 | 6.4k |
Countries citing papers authored by Christopher Stroh
Since
Specialization
Citations
This map shows the geographic impact of Christopher Stroh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Stroh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Stroh more than expected).
Fields of papers citing papers by Christopher Stroh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christopher Stroh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Stroh. The network helps show where Christopher Stroh may publish in the future.
Co-authorship network of co-authors of Christopher Stroh
This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Stroh. A scholar is included among the top collaborators of Christopher Stroh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Stroh. Christopher Stroh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rolfo, Christian, Aurora O’Brate, Rolf Bruns, et al.. (2025). Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib. Clinical Cancer Research. 31(13). 2675–2684.
2.
Pan, Hongming, Jean Frédéric Blanc, Véronique Grando, et al.. (2024). Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence. JCO Precision Oncology. 8(8). e2300328–e2300328.
3.
Albers, Joachim, Manja Friese‐Hamim, Oliver Schadt, et al.. (2023). The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations. Molecular Cancer Therapeutics. 22(7). 833–843.
4.
Ryder, Alex B., et al.. (2023). Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification.. Journal of Clinical Oncology. 41(16_suppl). e21057–e21057.
5.
Rolfo, Christian, C Menzel, Rolf Bruns, et al.. (2023). 1382P Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib. Annals of Oncology. 34. S793–S793.
6.
Silginer, Manuela, Eleanna Papa, Emese Szabó, et al.. (2023). Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition. Acta Neuropathologica Communications. 11(1). 41–41.
7.
Gupta, Parul, S. Hartl, Jennifer Furkel, et al.. (2023). Ythdf2 regulates cardiac remodeling through its mRNA target transcripts. Journal of Molecular and Cellular Cardiology. 181. 57–66.
8.
Le, Xiuning, Dariusz M. Kowalski, Byoung Chul Cho, et al.. (2021). OFP01.01 Liquid Biopsy to Detect MET Alterations in Patients with Advanced NSCLC: Biomarker Analysis from the VISION Study. Journal of Thoracic Oncology. 16(1). S7–S8.
9.
Viteri, Santiago, Julien Mazières, Rémi Veillon, et al.. (2020). 1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC. Annals of Oncology. 31. S831–S831.
10.
Nisa, Lluís, Paola Francica, Roland Giger, et al.. (2019). Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 19(2). 614–626.
11.
Cutsem, Eric Van, Heinz‐Josef Lenz, Claus-Henning Köhne, et al.. (2015). Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. Journal of Clinical Oncology. 33(7). 692–700.
12.
Amendt, Christiane, Eike Staub, Manja Friese‐Hamim, Stephan Störkel, & Christopher Stroh. (2014). Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer. Clinical Cancer Research. 20(17). 4478–4487.
13.
Ciardiello, Fortunato, Heinz‐Josef Lenz, Claus‐Henning Köhne, et al.. (2014). Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial.. Journal of Clinical Oncology. 32(3_suppl). LBA443–LBA443.
14.
O’Byrne, Kenneth J., U. Gatzemeier, Igor Bondarenko, et al.. (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. The Lancet Oncology. 12(8). 795–805.
15.
Cutsem, Eric Van, Claus-Henning Köhne, Erika Hitre, et al.. (2009). Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine. 360(14). 1408–1417.
16.
Tejpar, Sabine, Marc Peeters, Yves Humblet, et al.. (2008). The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab. Ghent University Academic Bibliography (Ghent University).
17.
Cutsem, Eric Van, István Láng, G D’Haens, et al.. (2008). The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri. Annals of Oncology. 19. 17–17.
18.
Tejpar, Sabine, Marc Peeters, Hans Gelderblom, et al.. (2008). Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study. Annals of Oncology. 19. 125–125.
19.
Łoś, Marek, et al.. (2003). Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discovery Today. 8(2). 67–77.
20.
Berg, Carla L. Van Den, Christopher Stroh, Susan G. Hilsenbeck, et al.. (1997). polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. European Journal of Cancer. 33(7). 1108–1113.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tae‐You Kim Breakdown of academic impact, for papers by Mario Scartozzi Breakdown of academic impact, for papers by Scott M. Wilhelm Breakdown of academic impact, for papers by Hans Prenen Breakdown of academic impact, for papers by Robert R. McWilliams Breakdown of academic impact, for papers by Weijing Sun Breakdown of academic impact, for papers by Li‐Tzong Chen Breakdown of academic impact, for papers by Moritz Koch Breakdown of academic impact, for papers by Teppei Morikawa Breakdown of academic impact, for papers by Ferry A.L.M. Eskens